What's next for psoriasis care? Neal Bhatia, M.D., associate clinical professor at Harbor-UCLA Medical Center and private practitioner at Therapeutics Dermatology, described formulation opportunities based on observations from a patient survey of the CeraVe product line, which he presented at the 2018 AAD meeting. He also gave thoughts on the next steps for this particular study.
!['Right now, I'm sure CeraVe will use these results to take a look at what market forces are driving [patient] choices, then look at whether there's a test market for psoriasis patients that they should be looking at to 'test ride' some of their topicals,' said Bhatia. '[Next, they may look at the therapeutic value of the products, instead of just how they feel. There are lots of doors yet to be open.'](https://img.cosmeticsandtoiletries.com/files/base/allured/all/image/2018/10/gci.Bhatia-headshot200.png?auto=format%2Ccompress&dpr=2&fit=max&q=70&w=700)
"Right now, I'm sure CeraVe will use these results to take a look at what market forces are driving [patient] choices, then look at whether there's a test market for psoriasis patients that they should be looking at to 'test ride' some of their topicals," said Bhatia. "[Next, they may look at the therapeutic value of the products, instead of just how they feel. There are lots of doors yet to be open."This three-part podcast series is based on the CeraVe study and explores differences in skin diseases, the industry's interest in the market for compromised skin, ingredient considerations and future studies.
Listen now to Part III, below; or review Part I or Part II.
